RCUS:NYE-Arcus Biosciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 12.45

Change

-0.10 (-0.80)%

Market Cap

USD 1.19B

Volume

0.47M

Analyst Target

USD 38.67
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin..

-0.18 (-0.47%)

USD 3.93B
NUVB Nuvation Bio Inc

-0.10 (-4.20%)

USD 0.78B
DNA Ginkgo Bioworks Holdings

-0.73 (-5.12%)

USD 0.62B
CYBN Cybin Inc

+0.37 (+4.11%)

USD 0.20B
PLX Protalix Biotherapeutics Inc

-0.11 (-4.14%)

USD 0.20B
ADCT ADC Therapeutics SA

-0.04 (-2.65%)

USD 0.16B
ANRO Alto Neuroscience, Inc.

-0.26 (-7.12%)

USD 0.12B
ARMP Armata Pharmaceuticals Inc

-0.06 (-2.88%)

USD 0.07B
OSTX OS Therapies Incorporated

-0.06 (-3.06%)

USD 0.07B
ANVS Annovis Bio Inc

-0.20 (-6.80%)

USD 0.06B

ETFs Containing RCUS

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.39% 34% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.39% 34% F 3% F
Trailing 12 Months  
Capital Gain -24.36% 68% D+ 9% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.36% 68% D+ 8% B-
Trailing 5 Years  
Capital Gain 10.57% 100% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.57% 87% B+ 38% F
Average Annual (5 Year Horizon)  
Capital Gain -1.90% 34% F 23% F
Dividend Return -1.90% 34% F 14% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 44.03% 71% C- 22% F
Risk Adjusted Return -4.32% 37% F 18% F
Market Capitalization 1.19B 97% N/A 60% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector